It will be the largest overseas acquisition by a Japanese company
Takeda Pharma, a Japanese firm has signed a deal to buy its UK-based rival Shire for 45.3 billion pounds ($61.50 billion). It is being touted as one of the largest pharma deals ever and the largest acquisition by a Japanese company.
Reportedly, the deal will propel Takeda in the big league and help it assume leadership position in gastroenterology, neuroscience, oncology, rare diseases, and blood-derived therapies.
Takeda’s bid was accepted after Shire rejected four offers due to price concerns. The deal is 46 per cent cash and 54 per cent stock, the UK-based company’s shareholders will own around half of the combined group.
Christophe Weber, CEO, Takeda said that the company is looking at growth in new markets for future progress.
Comments are closed.